Align Technology, Inc. vs Cronos Group Inc — how do they compare? Align Technology, Inc. trades at $172.77 (market cap $12.51B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Align Technology, Inc. is far larger — about 11.3× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | CRON | |
|---|---|---|
Market Cap | $12.51B | $1.11B |
Sector | Health | Health |
52-Week High | $197.51 | $3.27 |
52-Week Low | $124.88 | $2.30 |
Enterprise Value | $11.52B | $310.67M |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.66, up 2.71% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $2.64 surpassing the $2.62 estimate. Revenue reached a record $1.06 billion in Q2 2026, driven by clear aligner growth. Recent board changes and strategic initiatives aim to enhance long-term value.
The outlook is positive, supported by robust fundamentals and institutional interest, but risks include competitive pressures and scanner segment weakness. Valuation multiples remain below historical peaks, offering potential upside if growth accelerates. Investor sentiment is cautiously optimistic amid ongoing operational reviews.
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Trailing returns across standard periods
Latest headlines on both assets
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →